GlaxoSmithKline (GSK) Tops Q1 EPS by 18c

GlaxoSmithKline (NYSE: GSK) reported Q1 EPS of $1.20, $0.18 better than the analyst estimate of $1.02. Revenue for the quarter came in at $10.06 billion versus the consensus estimate of $9.48 billion.

For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.

You May Also Be Interested In

• Concentrix Corporation (CNXC) Misses Q2 EPS by 1c; Guides lower than expectations
• Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
• Tilray Brands acquires HelloMD to expand Canadian cannabis platform